home / stock / rhhbf / rhhbf quote
Last: | $255.60 |
---|---|
Change Percent: | 6.91% |
Open: | $254.51 |
Close: | $255.60 |
High: | $265.24 |
Low: | $254.51 |
Volume: | 58 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$255.6 | $254.51 | $255.6 | $265.24 | $254.51 | 58 | 04-26-2024 |
$273.4 | $254.51 | $273.4 | $273.4 | $254.51 | 90 | 04-25-2024 |
$275.03 | $270 | $275.03 | $275.03 | $270 | 258 | 04-24-2024 |
$267.835 | $269.5 | $267.835 | $271.37 | $267.835 | 1,727 | 04-23-2024 |
$256.31 | $256.31 | $256.31 | $256.31 | $256.31 | 33 | 04-22-2024 |
$254.5 | $252.374 | $254.5 | $269.5 | $252.374 | 21 | 04-19-2024 |
$263 | $263 | $263 | $263 | $263 | 48 | 04-18-2024 |
$262 | $262 | $262 | $262 | $262 | 300 | 04-17-2024 |
$269.5 | $248.18 | $269.5 | $269.5 | $248.18 | 157 | 04-16-2024 |
$255 | $251.96 | $255 | $255 | $251.96 | 108 | 04-15-2024 |
$265 | $269.5 | $265 | $269.5 | $265 | 88 | 04-11-2024 |
$265.8675 | $265 | $265.8675 | $265.8675 | $265 | 17 | 04-10-2024 |
$263 | $250.58 | $263 | $263 | $250.58 | 393 | 04-09-2024 |
$255 | $243.42 | $255 | $257.9 | $243.42 | 59 | 04-08-2024 |
$262 | $244.53 | $262 | $264 | $244.53 | 465 | 04-05-2024 |
$264 | $251.51 | $264 | $265.75 | $251.51 | 75 | 04-04-2024 |
$262.5 | $249.11 | $262.5 | $262.5 | $249.11 | 376 | 04-03-2024 |
$265.075 | $269 | $265.075 | $269 | $265 | 143 | 04-02-2024 |
$269 | $269.5 | $269 | $269.5 | $269 | 153 | 04-01-2024 |
$268.9 | $268.1 | $268.9 | $269.5 | $266.125 | 17 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd Company Name:
RHHBF Stock Symbol:
OTCMKTS Market:
Novartis AG (NYSE:NVS) reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches. The...
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive ...
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted a...